SCHEMBL5542225

SCHEMBL5542225

Cc1ccc2nc([O])ccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.63
NCK1 P16333 1/20 0.59
BACE1 P56817 1/20 0.59
CYP2A6 P11509 3/20 0.50
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NQO2 P16083 1/20 0.43
PDE3B Q13370 2/20 0.43
PDE3A Q14432 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542405 0.84 CYP1A2 (0.61) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL161703 0.77 CYP1A2 (1.00) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL23247265 0.77 CYP1A2 (0.68) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL29444268 0.77 CYP1A2 (1.00) CYP1A2NCK1BACE1CYP2A6ALDH1A1
Iodide SCHEMBL31142554 0.76 CYP1A2 (0.95) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL9755319 0.76 CYP1A2 (0.65) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL14330632 0.74 CYP1A2 (0.63) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL1133953 0.74 NCK1 (0.64) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL8287075 0.74 CYP1A2 (0.63) CYP1A2NCK1BACE1CYP2A6ALDH1A1
SCHEMBL7048523 0.74 BACE1 (1.00) CYP1A2NCK1BACE1CYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP1A2 659/4885NCK1 1888/4885BACE1 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.